lifestyle.pluralist.com

Author: ABBISKO THERAPEUTICS

AACR 2026 | Abbisko Therapeutics Showcases Six Research Advances Highlighting pan-KRAS, 4th Generation EGFR, and Synthetic Lethality Approaches

April 23, 2026
Abbisko Therapeutics’ FGFR4 Inhibitor Irpagratinib Granted Orphan Drug Designation by EMA for Hepatocellular Carcinoma

March 31, 2026
Abbisko Therapeutics’ FGFR2/3 Inhibitor ABSK061 Receives FDA IND Clearance for Achondroplasia in Children

March 31, 2026
Abbisko Therapeutics Announces FDA Acceptance of the NDA for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor

January 12, 2026